MedTrace Logo

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

NCT00769990 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-12-13

No results posted yet for this study

Summary

RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases.

PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in treating patients undergoing external-beam radiation therapy for pain caused by bone metastases.

Conditions

Interventions

DIETARY_SUPPLEMENT

genistein

Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).

RADIATION

radiation therapy

A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Shalamar Sibley, MD, MPH · Masonic Cancer Center, University of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-11-30
Completion
2010-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769990 on ClinicalTrials.gov